TFCP2L1-IN-1 is a specific small molecule targeting TFCP2L1 ’s active domain with anti-cancer activity. TFCP2L1-IN-1 synergizes with Sorafenib to induce Apoptosis and reduces cell proliferation, invasion, metastasis, clonal formation and sphere-forming capacity in hepatocellular carcinoma cells.